|
|
Clinical application value of Calcium Dibutyryladenosine Cyclophosphate combined with Salvianolate in acute myocardial infarction |
NI Wei-xin WU Qiang WANG Chu-lin LIN Yu-peng ZHANG Hua-di |
First Department of Cardiovascular Medicine,the People′s Hospital in Jieyang City,Guangdong Province,Jieyang 522000,China |
|
|
Abstract Objective To explore and analyze the clinical effect of Calcium Dibutyryladenosine Cyclophosphate combined with Salvianolate in acute myocardial infarction.Methods A total of 100 patients with acute myocardial infarction in our hospital from April 2016 to December 2017 were selected as experimental subjects and divided into two groups according to the treatment methods,50 cases in each group.The patients in the control group were treated with conventional treatment,and the patients in the observation group were treated with Calcium Dibutyryladenosine Cyclophosphate combined with Salvianolate.The heart function index level,GRACE coronary heart disease risk score,NIHSS heart function level and adverse event incidence were compared between the two groups.Results The total incidence of adverse events in the observation group(2.00%)was lower than that in the control group(24.00%),and the difference was statistically significant(P<0.05).After treatment,the proportion of NYHA cardiac function gradeⅠandⅡ in the observation group were significantly higher than those in the control group,while the proportion ofⅢandⅣgrade were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the LVEDD([48.51±2.37]mm)and LVESD([30.53±1.74]mm)in the observation group were lower than those in the control group([55.46±1.61],[42.94±1.52]mm),while the LVEF([56.52±5.74]%)in the observation group was higher than that in the control group([43.37±1.26]%),and the differences were statistically significant(P<0.05).After treatment,the GRACE coronary heart disease risk score in the observation group was(70.65±6.11)points,which was lower than that in the control group of(76.52±7.52)points,and the difference was statistically significant(P<0.05).Conclusion The treatment of patients with acute myocardial infarction with Calcium Dibutyryladenosine Cyclophosphate combined Salvianolate is effective and safe.
|
|
|
|
|
[1] |
厉永征,张清峰.复合辅酶联合二丁酰环磷腺苷钙治疗非ST段抬高性心肌梗死的效果观察[J].中国当代医药,2015,28(23):131-133,136.
|
[2] |
郑易,史习宝,潘荣荣,等.丹参多酚酸盐对急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗血流的影响[J].心脑血管病防治,2017,17(1):32-34.
|
[3] |
王静,郭其凤,汤进.心电图QRS波群时限与急性心肌梗死患者心功能及预后的相关性[J].重庆医学,2015,56(31):4413-4415.
|
[4] |
叶明,艾辉,曾玉杰,等.丹参多酚酸盐对急性心肌梗死PCI术后患者血管内皮和血小板活化功能的影响[J].安徽医药,2014,56(11):2178-2181.
|
[5] |
王喜福,张晓岩,叶明,等.丹参多酚酸盐对急性ST段抬高型心肌梗死患者介入治疗术后CD14+单核细胞黏附能力和ToLL样受体的影响[J].心肺血管病杂志,2017,36(2):82-85.
|
[6] |
李湘平,尹桃.丹参多酚酸盐注射液治疗冠心病的疗效观察[J].中国现代医学杂志,2010,20(4):619-621.
|
[7] |
何涛,何群,朱宇,等.丹参多酚酸盐治疗非ST段抬高型心肌梗死临床研究[J].中华全科医学,2014,12(5):735-736,774.
|
[8] |
宫胜东.丹参多酚酸盐对急性心肌梗死患者内皮功能及斑块炎症的影响[J].中国冶金工业医学杂志,2016,33(6):682-683.
|
[9] |
李林,吴龙飞,刘芙蓉,等.丹参多酚酸盐治疗急性心肌梗死疗效的研究[J].中国循证心血管医学杂志,2015,55(3):317-319.
|
[10] |
陈默,吴先军,杨小莉,等.不同治疗方案对急性ST抬高型心肌梗死PCI术后病人心功能及心肌微循环的影响[J].中西医结合心脑血管病杂志,2017,15(16):2034-2036.
|
[11] |
李红梅,冯品,张万玲,等.丹参多酚酸盐联合阿托伐他汀治疗老年急性心肌梗死对氧化应激损伤及炎性因子的影响[J].河北医药,2017,39(12):1842-1844,1847.
|
[12] |
凌鹏,廖振琦,张国庆,等.参麦注射液联合丹参多酚酸盐治疗急性心肌梗死急诊冠脉介入术后30例临床观察[J].江苏中医药,2014,58(12):21-23.
|
[13] |
汤秀英,李润军,荆全民,等.丹参多酚酸盐治疗急性心肌梗死临床效果评估[J].中国综合临床,2015,31(7):607-610.
|
[14] |
郭功亮,李晨昊,孙立群,等.丹参多酚酸盐对急性ST段抬高型心肌梗死患者血清中内脏脂肪素、基质金属蛋白酶-9及超敏C反应蛋白的影响[J].临床内科杂志,2016,33(9):614-616.
|
[15] |
可海霞,张金盈,贾银明,等.丹参多酚酸盐对老年急性心肌梗死患者血清妊娠相关蛋白-A脑钠肽和超敏C反应蛋白的影响[J].中华老年医学杂志,2014,33(10):1049-1052.
|
|
|
|